Paclitaxel with or without LCL161 in patients with breast cancer

• Research type

  Research Study

• Full title

  A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer.

• IRAS ID

  108007

• Contact name

  Peter Schmid

• Eudract number

  2012-000677-23

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This is a phase 2, randomized, two-arm, open-label, neoadjuvant, multicenter study in newly diagnosed women with triple-negative breast cancer. A total of 100 patients will be enrolled and treated, 50 patients in each arm of the study.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  12/SC/0429

• Date of REC Opinion

  24 Oct 2012

• REC opinion

  Further Information Favourable Opinion